You are here

Our science / Clinical Trials / Find a Trial / NCT00288639

Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).

Back to Search Print Save as PDF Bookmark Trial

NCT00288639

Last updated on May 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Athens, , 11526 Greece
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Epilepsy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Outpatients equal to or greater than 18 years of age with diagnosis of epilepsy with
partial seizures having minimum of two partial seizures during a two month period
before the baseline visit

- Having a clinical history of epilepsy and AED treatment at least 1 year prior to
inclusion

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- AED or Seizures/Epilepsy Related Exclusions:having a treatable cause of seizures

- Having absences seizures

- Having had status epileptics within the year prior to inclusion

- Having a progressive neurological or systematic disorder

- Having known significant renal or hepatic dysfunction

NCT00288639
Pfizer
Completed
Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Partial Seizures Epilepsy, Primary Generalized Tonic-Clonic Seizures Epilepsy
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
NCT01463306
All Genders
0+
Years
Multiple Sites
Epilepsy
An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures
NCT00372528
All Genders
18+
Years
Multiple Sites
Partial Epilepsy
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.
NCT00141414
All Genders
18+
Years
Multiple Sites
Partial Epilepsies, Complex Partial Epilepsy
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
NCT00143143
All Genders
18+
Years
Multiple Sites
Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).
Lyrica (Pregabalin) Administered As An Add-On Therapy For Partial Seizures (LEADER) An Open-Label, Multicenter Add-On Therapy Trial
The objective of study is to assess the clinical improvement (change in seizure frequency), safety, and tolerability of subjects with partial seizures following adjunctive therapy of pregabalin BID (150 to 600 mg/day titration) in addition to existing standards AEDs.
Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Epilepsy
Drug: Pregabalin

Pregabalin treatment, given as 2 divided doses, is initiated at a dose of 150 mg/day (75 mg BID).

Based on individual subject response and tolerability, the dosage may be increased to 300 mg/day after 1 week (150 mg BID given as two 75-mg capsules BID). Based on subjects individual response and tolerability, dosage can be incrementally increased further after an additional week to 600 mg/day (300 mg BID given as four 75-mg capsules BID).
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
98
December 2007
December 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Outpatients equal to or greater than 18 years of age with diagnosis of epilepsy with partial seizures having minimum of two partial seizures during a two month period before the baseline visit
  • Having a clinical history of epilepsy and AED treatment at least 1 year prior to inclusion

Exclusion Criteria:

  • AED or Seizures/Epilepsy Related Exclusions:having a treatable cause of seizures
  • Having absences seizures
  • Having had status epileptics within the year prior to inclusion
  • Having a progressive neurological or systematic disorder
  • Having known significant renal or hepatic dysfunction
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Greece
 
 
NCT00288639
A0081088
No
Not Provided
Not Provided
Clinical Trials Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
August 2009

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now